SCHEMBL3323535

SCHEMBL3323535

CCC1(CC)CC(N)c2cccc(F)c2O1

nearest known ligand 0.43

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 16/20 0.43
KDM1A O60341 3/20 0.42
RCOR1 Q9UKL0 1/20 0.42
KDM1B Q8NB78 1/20 0.37
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3323531 1.00 TRPV1 (0.43) TRPV1KDM1ARCOR1KDM1BHTR2C
SCHEMBL3323044 0.89 TRPV1 (0.45) TRPV1KDM1ARCOR1KDM1BHTR2C
SCHEMBL3323037 0.89 TRPV1 (0.45) TRPV1KDM1ARCOR1KDM1BHTR2C
SCHEMBL2317663 0.87 TRPV1 (0.41) TRPV1KDM1ARCOR1KDM1BHTR2C
SCHEMBL2317667 0.87 TRPV1 (0.41) TRPV1KDM1ARCOR1KDM1BHTR2C
SCHEMBL3323466 0.82 KDM1A (0.37) TRPV1KDM1ARCOR1KDM1BHTR2C
SCHEMBL3321846 0.82 KDM1A (0.37) TRPV1KDM1ARCOR1KDM1BHTR2C
SCHEMBL3324005 0.82 KDM1A (0.37) TRPV1KDM1ARCOR1KDM1BHTR2C
SCHEMBL3325412 0.82 PNMT (0.38) TRPV1KDM1ARCOR1HTR2CHTR2B
SCHEMBL3325405 0.82 PNMT (0.38) TRPV1KDM1ARCOR1HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796328-B2 TRPV1 antagonists ABBVIE INC. 2014-08-05 US disclosed
US-20130345255-A1 TRPV1 ANTAGONISTS ABBVIE INC. 2013-12-26 US disclosed
US-8609692-B2 TRPV1 antagonists ABBVIE INC. (US) 2013-12-17 US disclosed
US-8604053-B2 TRPV1 antagonists ABBVIE INC. (US) 2013-12-10 US disclosed
US-20100137360-A1 TRPV1 ANTAGONISTS ABBOTT LABORATORIES (US) 2010-06-03 US disclosed
US-20100120846-A1 TRPV1 ANTAGONISTS ABBOTT LABORATORIES (US) 2010-05-13 US disclosed
US-20090143423-A1 SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND ABBOTT GMBH & CO. KG (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137360-A1 TRPV1 ANTAGONISTS TRPV1, TRPV3, TRPV2 TRPV1 1/4885KDM1A 3338/4885RCOR1 462/4885
US-20100120846-A1 TRPV1 ANTAGONISTS TRPV1, TRPV3, TRPV2 TRPV1 1/4885KDM1A 3414/4885RCOR1 451/4885
US-20130345255-A1 TRPV1 ANTAGONISTS TRPV1, NPY1R, OPRL1 TRPV1 1/4885KDM1A 2853/4885RCOR1 320/4885
US-20090143423-A1 SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND U2SURP, UMPS, HNRNPUL1 TRPV1 4781/4885KDM1A 582/4885RCOR1 3230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.